All In Biotech

Drug Trial Radar · NCT04037605

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

Last checked: Nov 20, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

5

Actual

Start

Feb 9, 2020

Primary completion

Jul 24, 2022

Study completion Jun 24, 2026

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jul 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to 1) determine how hypothalamic-pituitary-adrenal axis (HPA axis) activation occurs with sleep restriction and 2) evaluate how hypothalamic-pituitary-gonadal axis (HPG axis) deactivation occurs with sleep restriction. The investigator will also examine the cognitive function associated with sleep restriction, including food intake and food cravings.

Conditions

  • Sleep Restriction

Interventions

  • Ketoconazole Pill (also known as nizoral)Drug

    Ketoconazole pill is taken 4 times per inpatient visit

  • GanirelixDrug

    Ganirelix subcutaneous injection is administered twice per inpatient visit

  • Dexamethasone PillDrug

    Dexamethasone pills is taken twice per inpatient visit

  • Dexamethasone injectionDrug

    Dexamethasone IV injection is given twice per inpatient visit

  • Cosyntropin Injectable ProductDrug

    Cosyntropin injection is given twice per inpatient visit

  • Recombinant Human Luteinizing Hormone (also known as luveris)Drug

    Recombinant Human Luteinizing Hormone is given as 6 IV infusion pulses per inpatient visit

  • Hydrocortisone Injection (also known as solu-cortef)Drug

    Hydrocortisone IV push is given twice per inpatient visit

  • Gonadorelin (also known as Lutrepulse)Drug

    Gonadorelin IV injection is given twice per inpatient visit

  • Corticorelin (also known as Acthrel)Drug

    Corticorelin IV injection is given twice per inpatient visit

  • Placebo oral tabletDrug

    Placebo for Ketoconazole are given 4 times per inpatient visit

  • Saline SolutionDrug

    Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per inpatient visit

  • Saline solution for injectionDrug

    Saline Solution (placebo) for ganirelix subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average Blood Cortisol ConcentrationTime frame: 5 days
  2. Average Blood Testosterone ConcentrationTime frame: 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Los Angeles Biomedical Research Institute

    Torrance, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.